1st Quarter - Report
WAXMAN STRATEGIES for 340B HEALTH
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Firm
Client
Income
$25,000
Expenses
—
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 20, 2026 | $25,000 | Replaced |
| 1st Quarter - Amendment | Apr 20, 2026 | $39,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues affecting the 340B drug pricing program, drug prices, and health care costs
| Lobbyist | Covered position, as disclosed |
|---|---|
| HELEN ROBINS New | — |
| JEREMY SHARP New | LA,Rep Capps 2001-05 PSM, Sen HELP Comm 2007-10 LD, Sen Dodd 2010 DAS for Leg, HHS, 2011-13 Counselor, HHS, 2013-14 Dep Commissioner for Policy, FDA 2015-17 |
| HENRY WAXMAN | US House of Representatives 1975 to 2015 |
Pharmacy PHA
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HELEN ROBINS New | — |
| JEREMY SHARP | LA,Rep Capps 2001-05 PSM, Sen HELP Comm 2007-10 LD, Sen Dodd 2010 DAS for Leg, HHS, 2011-13 Counselor, HHS, 2013-14 Dep Commissioner for Policy, FDA 2015-17 |
| HENRY WAXMAN | US House of Representatives 1975 to 2015 |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.